<?xml version="1.0" encoding="UTF-8"?>
<ref id="R58">
 <label>58. •</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Darcis</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Binda</surname>
   <given-names>CS</given-names>
  </name>, 
  <name>
   <surname>Klaver</surname>
   <given-names>B</given-names>
  </name>, 
  <name>
   <surname>Herrera-Carrillo</surname>
   <given-names>E</given-names>
  </name>, 
  <name>
   <surname>Berkhout</surname>
   <given-names>B</given-names>
  </name>, 
  <name>
   <surname>Das</surname>
   <given-names>AT</given-names>
  </name>: 
  <article-title>The impact of HIV-1 genetic diversity on CRISPR-Cas9 antiviral activity and viral escape</article-title>. 
  <source>Viruses</source>
  <year>2019</year>, 
  <volume>11</volume>.
 </mixed-citation>
 <note>
  <p id="P37">In this report, the impact of HIV genetic diversity on dual-gRNA CRISPR–Cas9 antiviral activity and viral escape is described. It is shown that combinatorial CRISPR–Cas9 treatment can cure T cells infected by distinct HIV isolates, but even minor sequence variation in conserved viral target sites, in particular at the Cas9 cleavage site, can affect the efficacy. Successful cure attempts against isolates with divergent target sequences may therefore require adaptation of the gRNAs.</p>
 </note>
</ref>
